Drug - Zytiga (abiraterone acetate) [Centocor Ortho Biotech]
Therapeutic Area - Oral Oncology
- Patient has metastatic castration-resistant prostate cancer AND
- Will be on prednisone concurrently AND
- Has had previous chemotherapy with docetaxel OR
- Is not a chemotherapy candidate and in the pre-docetaxel setting
The initial PA will allow a first fill of 14 days [56 tablets (4 tablets once daily)] with one refill to ensure patient tolerance with therapy before approving in larger, monthly quantities.
Monthly Quantity Limit = 136
Zytiga (abiraterone acetate) is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received chemotherapy containing docetaxel.
The 1.2013 NCCN guidelines for prostate cancer place abiraterone acetate as an alternative to ketoconazole for patients with metastatic disease without symptomatic visceral disease, or after docetaxel in patients with symptomatic visceral disease. Imitinib is considered first-line treatment.
MHCP Provider Call Center 651-431-2700 or 800-366-5411